
Galactosemia: Genetic Testing's Role in Managing a Metabolic Mystery
Raised galactose in a newborn blood test points to galactosemia, and GALT, GALK1 or GALE analysis shows which Leloir pathway enzyme is missing.

MD · MBA
Physician specializing in genetic analysis and personalized preventive medicine, and author of Outsmart Your Genes.
Brandon Colby is a physician-expert in the fields of genetic analysis and Personalized Preventive Medicine. He holds an MD from the Mount Sinai School of Medicine, an MBA from Stanford University's Graduate School of Business, and a degree in Genetics from the University of Michigan.
Dr. Colby is the author of the book Outsmart Your Genes and has developed numerous technologies that improve the analysis, interpretation, and actionability of genome sequencing data. He is an Affiliate Specialist of the American College of Medical Genetics and Genomics (ACMG), an Associate of the American College of Preventive Medicine (ACPM), and a member of the National Society of Genetic Counselors (NSGC).
Articles by Brandon Colby, MD are reviewed for accuracy by Sequencing's medical and scientific team. This page is for informational purposes and does not constitute medical advice.

Raised galactose in a newborn blood test points to galactosemia, and GALT, GALK1 or GALE analysis shows which Leloir pathway enzyme is missing.

Numerous polyps in the upper stomach can progress to gastric adenocarcinoma in this autosomal dominant syndrome; testing identifies relatives who need endoscopy.

Anemia, an enlarged spleen and bone pain can be mistaken for other illnesses; GBA gene analysis confirms Gaucher disease and can guide enzyme replacement dosing.

Changes in the glucagon receptor gene raise glucagon levels and can disturb metabolism; GCGR testing separates this rare condition from other metabolic disorders.

Febrile seizures that persist or turn afebrile run in families with GEFS+, where mutations in SCN1A, SCN1B and GABRG2 are found, though not all are detectable.

Profiling a tumor reveals the mutations driving its growth; research points to OGDH, whose inhibition alongside Bcl-xL blockade was synthetically lethal in cells.

Children with this rare syndrome may show developmental delay, lung cysts, overgrowth and a predisposition to Wilms tumor, which genetic testing helps confirm.

Rare and hard to recognize, GDD-VAPCAT Syndrome pairs developmental delay with visual anomalies, progressive cerebellar atrophy and truncal hypotonia.